Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3/TGFβ-CAR-T in Advanced HCC
NCT03198546Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2017
- Primary completion
- Aug 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD5851 in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Dose Limiting Toxicity at 3 months. Started Jul 2017; status: recruiting.
02
Drugs
AZD5851
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03198546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198546.